RPL36A: A Protein Linked To Cancer and Neurodegenerative Diseases

Target Name: RPL36A

NCBI ID: G6173

RPL36A

RPL36A: A Protein Linked To Cancer and Neurodegenerative Diseases

Ribosomal subunit protein EL42, or RPL36A, is a protein that is expressed in nearly all eukaryotic cells and is involved in the process of translation of mRNAs into proteins. Mutations in RPL36A have been linked to a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, RPL36A has become a focus of interest for researchers as a potential drug target or biomarker.

The RPL36A protein is a large ribosomal subunit protein that contains 256 amino acids. It is expressed in a variety of tissues and cells, including muscle, nerve, heart, and liver cells. RPL36A is primarily localized to the endoplasmic reticulum (ER) and is involved in the process of protein translation, which is the process by which mRNAs are translated into proteins.

RPL36A plays a crucial role in the regulation of protein translation. It is a component of the machinery that transports mRNAs from the ER to the cytoplasm, where they can be translated into proteins by the ribosome. RPL36A helps to maintain the stability of this machine by interacting with the ribosome and the mRNA.

In addition to its role in protein translation, RPL36A has also been shown to play a role in the regulation of cellular processes that are important for the survival and growth of cells. For example, RPL36A has been shown to be involved in the regulation of cell. cycle progression, and has been linked to the development of cancer.

Mutations in RPL36A have been linked to a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that RPL36A mutations are associated with an increased risk of the development of colon cancer. Additionally, RPL36A mutations have also has been linked to the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

As a result, RPL36A has become a focus of interest for researchers as a potential drug target or biomarker. Researchers are working to develop small molecules that can interact with RPL36A and inhibit its activity, potentially leading to the development of new treatments for a variety of diseases. For example, researchers have synthesized a small molecule that has been shown to inhibit the activity of RPL36A and has shown promise in the treatment of neurodegenerative diseases.

In conclusion, RPL36A is a protein that is involved in the process of translation of mRNAs into proteins and has been linked to a variety of diseases. As a result, RPL36A has become a focus of interest for researchers as a potential drug target or biomarker. Further research is needed to fully understand the role of RPL36A in the regulation of protein translation and the development of disease.

Protein Name: Ribosomal Protein L36a

Functions: Component of the large ribosomal subunit. The ribosome is a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell

The "RPL36A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL36A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets